Acalabrutinib Generic: A Cost-Effective BTK Inhibitor for Blood Cancer Treatment
Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor used primarily in the treatment of certain B-cell malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). The availability of its generic version marks a significant advancement in making targeted cancer therapies more accessible and affordable.
Visit: https://medspartner.com/
Like
Comment
Share
